News

Filter

1 to 9 of 53 results

Positive early results for Boehringer Ingelheim’s investigational antidote idarucizumab

19-11-2014

The US subsidiary of German family-owned pharma major Boehringer Ingelheim has presented Phase I study…

Boehringer IngelheimCardio-vascularHematologyidarucizumabPharmaceuticalPradaxaResearch

Boehringer Ingelheim start Phase III trial on idarucizumab as antidote to Pradaxa

Boehringer Ingelheim start Phase III trial on idarucizumab as antidote to Pradaxa

12-11-2014

German family-owned drug major Boehringer Ingelheim has initiated a global Phase III study on idarucizumab,…

Boehringer IngelheimHematologyidarucizumabPharmaceuticalPradaxaResearch

FDA study shows Pradaxa reduces stroke risk but raises chances of GI bleeding

FDA study shows Pradaxa reduces stroke risk but raises chances of GI bleeding

03-11-2014

A study carried out by the US Food and Drug Administration on Pradaxa (dabigatran etexilate mesylate)…

Boehringer IngelheimHematologyPharmaceuticalPradaxaRegulationResearchUSAWarfarin Sodium

NICE recommends Pradaxa for DVT and PE

NICE recommends Pradaxa for DVT and PE

31-10-2014

In draft guidance published today, the UK health costs watchdog the National Institute for Health and…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulationUK

Boehringer Ingelheim gets two drugs approved by Scotland’s health watchdog

14-10-2014

The UK subsidiary of German family-owned pharma major Boehringer Ingelheim announced today that, following…

Boehringer IngelheimCardio-vascularDiabetesJardiancePharmaceuticalPradaxaPricingUK

Boehringer plans new real-world data on Pradaxa

01-09-2014

Five years on from the first breakthrough presentation of the pivotal RE-LY clinical trial of Pradaxa…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaResearch

Brazil and Mexico physicians’ preferences on anticoagulants

25-07-2014

Novel oral anticoagulants (NOACs) such as Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa…

BayerBoehringer IngelheimBrazilBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingMexicoPfizerPharmaceuticalPradaxaPricingXarelto

BMJ alleges Boehringer Ingelheim withheld Pradaxa dosing information from regulators

BMJ alleges Boehringer Ingelheim withheld Pradaxa dosing information from regulators

24-07-2014

German family-owned drug major Boehringer Ingelheim has been accused of withholding ‘important analyses’…

Boehringer IngelheimDabigatranGermanyHematologyPharmaceuticalPradaxaPyridinesRegulationUKUniversity of California

1 to 9 of 53 results

COMPANY SPOTLIGHT

Menarini

Back to top